Accessibility Menu
Idexx Laboratories logo

Idexx Laboratories(NASDAQ) IDXX

Market Cap$46.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)+62,111%
5 Year-17%
1 Year-14%
1 Month+5%
$587.20
-0.15%
-0.89Today
Idexx Laboratories last closing stock price
MetricPriceDate
Last closeUSD 588.092026-08-04
Idexx Laboratories stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.26%USD 569.542026-07-28
1 month+5.43%USD 557.802026-07-02
3 month+1.53%USD 579.232026-05-06
Year to date-13.07%USD 676.532025-12-31
1 year-13.87%USD 682.782025-08-04
3 year+16.67%USD 504.082023-08-04
5 year-16.67%USD 705.762021-08-05
Since inception+62,111.21%USD 0.951991-06-21

Idexx Laboratories Financials at a Glance

Market Cap

$46.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.55B

Net Income (TTM)

$1.14B

EPS (TTM)

$13.59

P/E Ratio

43.27

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$587.20

Volume

299,708.018

Open

$590.22

Previous Close

$588.09

Daily Range

$580.68 - $604.14

52-Week Range

$518.55 - $769.98

Estimated Earnings Date

Nov 2, 2026

IDXX News

Boy holds up globe in green field.

10 Best ESG Investing Stocks for 2026 and How to Invest

Jeremy BowmanJun 17, 2026
GettyImages-1553902230

Got $5,000? Here's the Ultimate Pick-and-Shovel Pet Stock (Spoiler: It's Not Chewy)

Josh Kohn-LindquistFeb 20, 2026
Dog looking at camera with its mouth open

Why Idexx Laboratories Stock Surged by Almost 15% Today

Eric VolkmanNov 3, 2025
GettyImages-1516239450 (1).jpg

Seilern Investment Management Sells $43 Million Worth of IDEXX Laboratories (NASDAQ: IDXX) Stock

Josh Kohn-LindquistOct 14, 2025
investor in business attire reviews information on a tablet

These Were the 5 Top-Performing Stocks in the S&P 500 in August 2025

Jon QuastSep 4, 2025
Foolcom-Featured.png

Idexx (IDXX) Q2 Revenue Jumps 11%

Motley Fool Markets TeamAug 4, 2025
GettyImages-1553902230 (1)

Meet the Little-Known S&P 500 Stock That Has Rocketed 10,230% Higher Since 2000

Josh Kohn-LindquistMar 29, 2025
GettyImages-1725491683 (1)

Why Idexx Labs Stock Rocketed Higher This Week

Josh Kohn-LindquistFeb 7, 2025
Page 1

IDXX: Motley Fool Moneyball Superscore

83

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Idexx Laboratories

IDEXX makes tools that help veterinarians check the health of pets through blood and urine tests. They also provide testing kits to keep drinking water safe and livestock healthy. Their products give doctors and farmers fast, accurate results to treat animals better.

The Diagnostic Toolkit

  • Companion Animal Group: Provides point-of-care analyzers, rapid test kits, and reference laboratory services for pets; also includes practice management software and digital imaging systems.
  • Water Quality Products: Offers tests that detect bacterial contaminants like E. coli and coliforms in water; used by utilities and labs to meet safety standards.
  • Livestock, Poultry and Dairy: Produces diagnostic tests to manage herd health and screening tools to ensure the quality and safety of milk.
  • Human Medical Diagnostics: Sells point-of-care blood gas and electrolyte analyzers used in human hospitals and clinics.

New Tools and Targets

  • Launched the IDEXX Cancer Dx Panel in North America during 2025 to help veterinarians screen dogs for lymphoma through blood tests.
  • Introduced the IDEXX inVue Dx Cellular Analyzer in late 2024, which uses artificial intelligence to automate cytology testing in clinics.
  • Released the ImageVue DR50 Plus in North America in January 2026 to provide high-definition digital X-rays with lower radiation doses.
  • Expanded the UV Viewer Plus bench-top cabinet in 2025 to help laboratory technicians read fluorescent-based water tests more easily.

What Makes IDEXX Different

The company maintains a global network of roughly 80 reference laboratories and employs over 11,000 people across 34 countries. Their competitive edge comes from integrating diagnostic hardware with cloud-based software, allowing veterinarians to see all patient data in one digital file.

The Recent Numbers

  • Revenue reached $1.1 billion in Q4 2025, representing a 14.3% increase from Q4 2024.
  • Net income rose to $248.2 million in Q4 2025, up 14.8% from the $216.1 million reported in Q4 2024.
  • Free cash flow grew to $322.6 million in Q4 2025, a 44.8% jump year-over-year.
  • Operating income hit $315.6 million in Q4 2025, up 20.6% compared to $261.7 million in Q4 2024.

Bottom Line

IDEXX has grown from a specialized testing firm into a global leader in veterinary technology and water safety. Its shift toward cloud-based software and artificial intelligence continues to change how animal healthcare providers manage their daily operations.

AI Generated • Apr 18, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

11,000

CEO

Jonathan J. Mazelsky, MBA

Website

www.idexx.com

Headquarters

Westbrook, ME 04092, US

IDXX Financials

Key Financial Metrics (TTM)

Gross Margin

62.45%

Operating Margin

32.03%

Net Income Margin

25.03%

Return on Equity

71.96%

Return on Capital

50.70%

Return on Assets

33.11%

Earnings Yield

2.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$46.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

78.88M

Volume

299.71K

Avg. Volume

667.72K

Financials (TTM)

Gross Profit

$2.84B

Operating Income

$1.46B

EBITDA

$1.54B

Operating Cash Flow

$1.37B

Capital Expenditure

-$117.18M

Free Cash Flow

$1.25B

Cash & ST Invst.

$196.93M

Total Debt

$968.86M

Idexx Laboratories Performance Analysis

Idexx Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,367,324,0004.7%
20232023-12-31USD 3,660,953,0008.7%
20242024-12-31USD 3,897,504,0006.5%
20252025-12-31USD 4,303,702,00010.4%
Idexx Laboratories sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-0.4%
Q42025-12-31-1.3%
Q12026-03-314.6%
Q22026-06-306.6%
Idexx Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 8.03-6.7%
20232023-12-31USD 10.0625.4%
20242024-12-31USD 10.676.0%
20252025-12-31USD 13.0822.6%
Idexx Laboratories sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-6.3%
Q42025-12-31-9.4%
Q12026-03-3112.0%
Q22026-06-3021.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.22B

+9.7%

Gross Profit

$779.09M

+12.1%

Gross Margin

64.04%

N/A

Market Cap

$46.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.22M

N/A

Employees

11,000

N/A

Net Income

$338.41M

+15.1%

EBITDA

$387.29M

-5.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$196.93M

+19.6%

Total Debt

$968.86M

-21.7%

Accounts Receivable

$627.08M

-5.5%

Inventory

$391.58M

-0.3%

Long Term Debt

$299.87M

-46.2%

Short Term Debt

$669.00M

-1.6%

Return on Assets

33.11%

N/A

Return on Invested Capital

67.69%

N/A

Free Cash Flow

$322.52M

+112.7%

Operating Cash Flow

$347.16M

+86.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EWEdwards Lifesciences Corporation
$88.75-0.95%
AAgilent Technologies, Inc.
$140.82+1.16%
ARGXargenx SE
$865.47+2.48%
IQVIQVIA Holdings Inc.
$236.68+3.72%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$115.31-0.08%
NVDANvidia
$221.47+0.04%
INLFInlif
$6.47+1.03%
INTCIntel
$102.34+0.01%

Questions About IDXX

What is the current price of Idexx Laboratories?

Idexx Laboratories is trading at $587.83 per share.

What is the 52-week range for Idexx Laboratories?

Over the past 52 weeks, Idexx Laboratories has traded between $518.55 and $769.98.

How much debt does Idexx Laboratories have?

As of the most recent reporting period, Idexx Laboratories reported total debt of $1.11B.

How much cash does Idexx Laboratories have on hand?

Idexx Laboratories reported $200.53M in cash and cash equivalents in its most recent financial results.

What is Idexx Laboratories’s dividend yield?

Idexx Laboratories does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services